CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.
about
Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and SafetyElectroacupuncture at Fengchi (GB20) inhibits calcitonin gene-related peptide expression in the trigeminovascular system of a rat model of migraine.Anti-CGRP monoclonal antibodies in migraine: current perspectives.Migraine: multiple processes, complex pathophysiology.Scientometrics of drug discovery efforts: pain-related molecular targets.Dural administration of inflammatory soup or Complete Freund's Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion.Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage.The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms.Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine.The Journey to Establish CGRP as a Migraine Target: A Retrospective View.The role of anti-CGRP antibodies in the pathophysiology of primary headaches.Childhood Maltreatment in the Migraine Patient.Chronic migraine treatment: from OnabotulinumtoxinA onwards.Induction of calcitonin gene-related peptide expression in rats by cortical spreading depression.The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine.Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?Heteroreceptors Modulating CGRP Release at Neurovascular Junction: Potential Therapeutic Implications on Some Vascular-Related Diseases.Blocking CGRP in migraine patients - a review of pros and cons.Triptans and CGRP blockade - impact on the cranial vasculature.Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.Schwann cell TRPA1 mediates neuroinflammation that sustains macrophage-dependent neuropathic pain in mice.CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior.In situ imaging reveals properties of purinergic signalling in trigeminal sensory ganglia in vitro.Recognizing the role of CGRP and CGRP receptors in migraine and its treatment.CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.CGRP and its receptors.The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel.The pathophysiology of the trigeminal autonomic cephalalgias, with clinical implications.The CGRP receptor antagonist BIBN4096 inhibits prolonged meningeal afferent activation evoked by brief local K+ stimulation but not cortical spreading depression-induced afferent sensitization.Probing the mechanism of receptor activity-modifying protein modulation of GPCR ligand selectivity through rational design of potent adrenomedullin and calcitonin gene-related peptide antagonists.Menstrual migraine: a review of current and developing pharmacotherapies for women.Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats.Vascular Contributions to Migraine: Time to Revisit?
P2860
Q26801753-D59E91D5-5DAF-4DBF-8C02-822C2DEA20A9Q33771288-58FE094D-2210-427A-B8E1-BCE1E69D62FBQ34531880-CB3605D1-A9B3-41AD-A845-BA16D4EDBB6EQ35547845-980BAC29-8B1F-4683-A9FD-577B7BD91EF1Q35821972-93856A73-54DF-487F-8207-1799C7BD3E7FQ36017049-3CE84579-9675-4A85-9253-DCC367CFF35FQ36233055-C20F4E44-AE8C-4D33-8976-68E57C44F702Q36340711-3418779C-8492-4868-8CE1-7F39782C0AC3Q37558868-28292039-A512-453C-9832-9C48B50DEB49Q37686124-41806DCD-984E-4119-9676-74141AE42501Q37713262-97929BC4-3C45-484C-A0CD-210F999F1037Q38561443-0C195CBC-AF9B-45E8-AF27-798A33E5F021Q38681565-C085D1FE-5DC1-42F3-8E9D-45953A62519DQ38838022-2A19E5A2-A8FE-4195-988D-876AB8C4E01EQ38866988-1C5634CA-CB13-4472-93DE-6FDCFBD0FA7DQ39129824-59D3EB7D-5337-4C26-8885-7F56B48056BBQ39155905-AE92B412-C5D7-4A07-9AD3-500B19933C47Q39242677-A8C871DC-89D5-4EAA-A699-ADD0972D4958Q39400059-A5365A90-B6C9-4187-BAAE-CD1EE890DA92Q41085676-5A7547B9-9FDA-45E0-A692-AD98ACB03E57Q42363673-63FA00AE-3287-4160-863A-C3EB2BD01483Q42706186-B48F5AA4-9DA4-4436-B5BD-4D881E59FC1FQ47095158-CA09C86D-14BE-4629-99C4-359174C07330Q47101699-F34DF266-F758-4E8C-952D-415C55A4AB84Q47710418-5CA96C45-47EC-4A77-AB25-B3E81FCA1A29Q47777431-C2BB0B68-E0B2-4172-8AC5-C3B0496AF1ACQ47819343-CF6C4EE2-24D2-4F33-88A0-8AD234A23D04Q47979735-1616AE0D-B3D2-4881-BFAE-EF6DE0BAE6F1Q48198655-BCAAD960-18F4-4895-B8EB-7929E3FBC080Q48264984-9BB39E1B-8BEE-40FB-873C-334D1C8A48E7Q48300154-4C3A7825-43F7-4157-ABAB-F853A7FD96E5Q49548019-5AEF08D8-2E53-41AE-B032-124197084036Q49832472-622E8D83-D8C5-496E-B3D6-A55D67A9866BQ50047547-F76CE06C-4B15-498C-837F-5D4A257343ACQ53745293-61B4DF0B-5B3C-4935-BADC-99A09DC7031CQ58801458-BABD9057-07B9-4903-84EF-87487F41D491
P2860
CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
CGRP receptor antagonists and ...... eceptor in migraine treatment.
@en
CGRP receptor antagonists and ...... eceptor in migraine treatment.
@nl
type
label
CGRP receptor antagonists and ...... eceptor in migraine treatment.
@en
CGRP receptor antagonists and ...... eceptor in migraine treatment.
@nl
prefLabel
CGRP receptor antagonists and ...... eceptor in migraine treatment.
@en
CGRP receptor antagonists and ...... eceptor in migraine treatment.
@nl
P2860
P356
P1476
CGRP receptor antagonists and ...... receptor in migraine treatment
@en
P2093
Lars Edvinsson
P2860
P304
P356
10.1111/BCP.12618
P407
P577
2015-05-19T00:00:00Z